GlassScriptPhysician profile
Karo K Arzoo
NPI 1306862859
$6,658.84
in general payments reported to CMS, 2019-2025
18 companies · $319 in 2025
The $319 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $255 · 2020: $13.34 · 2021: $2,555 · 2022: $250 · 2023: $734 · 2024: $2,532 · 2025: $319.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,010 · Food and Beverage: $1,330 · Education: $245.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,010.00 |
| Food and Beverage | $1,330.20 |
| Education | $245.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,350.28 | 2021-2024 | Enhertu |
| Glaxosmithkline, LLC. | $1,964.48 | 2021-2023 | Zejula |
| E.R. Squibb & Sons, L.L.C. | $479.42 | 2021-2024 | Opdivo |
| Dendreon Pharmaceuticals LLC | $305.01 | 2023-2025 | Provenge |
| Amgen INC. | $218.79 | 2019-2021 | |
| Lilly USA, LLC | $214.86 | 2021-2025 | Verzenio, Jaypirca |
| Gilead Sciences, INC. | $177.41 | 2021-2024 | |
| Menarini Silicon Biosystems, INC. | $146.53 | 2025 | |
| Daiichi Sankyo INC. | $140.65 | 2023 | Enhertu |
| Karyopharm Therapeutics INC. | $133.68 | 2021-2023 | Xpovio |
| Genzyme Corporation | $129.16 | 2023 | |
| Incyte Corporation | $123.64 | 2019 | |
| Janssen Biotech, INC. | $84.99 | 2023 | Erleada |
| Pfizer INC. | $75.09 | 2019-2025 | |
| Agilent Technologies, INC. | $64.93 | 2023 | Ctdx First |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | $17.63 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.40 | 2023 | Fruzaqla |
| Tempus Ai, INC | $15.89 | 2025 | Xt Cdx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karo Arzoo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.